OPKO Health Inc. [NASDAQ: OPK] closed the trading session at $4.86 on 08/13/20. The day’s price range saw the stock hit a low of $4.64, while the highest price level was $5.00. The company report on August 12, 2020 that OPKO Health’s GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services.
GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), the global leader in neonatal and pediatric genetic testing, announced the entrance into an agreement with Pediatrix Medical Group (“Pediatrix”), the nation’s leading provider of maternal-fetal, and pediatric medical and surgical subspecialty physician services, to offer state-of-the-art, next-generation genomic sequencing to support clinical diagnosis in neonatal intensive care units (“NICUs”) staffed by Pediatrix’s affiliated neonatologists. The sequencing is designed to enhance diagnostic capabilities in order to lessen the impact of disease and facilitate the development of novel precision medicine solutions for pediatric care. The initial offering will include whole exome and whole genome sequencing and genomic support services under the brand Detect Genomix and the initial clinical diagnostic support services will be made available to hospitals and patients across the country.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
“Our innovative technology, advanced analytics, customized genomic reports and genetic counseling offerings coupled with Pediatrix’s vast neonatal clinical experience and expansive coverage across the country set the stage for this arrangement to provide the first comprehensive offering of this type to hospitals and health systems nationwide,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories and GeneDx. .
The stocks have a year to date performance of 230.27 percent and weekly performance of -14.15 percent. The stock has been moved at 209.24 percent over the last six months. The stock has performed 19.14 percent around the most recent 30 days and changed 89.65 percent over the most recent 3-months.
If compared to the average trading volume of 17.81M shares, OPK reached to a volume of 8442680 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about OPKO Health Inc. [OPK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OPK shares is $8.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OPK stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Jaffray have made an estimate for OPKO Health Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 25, 2019. The new note on the price target was released on March 02, 2018, representing the official price target for OPKO Health Inc. stock. On June 21, 2016, analysts increased their price target for OPK shares from 16 to 18.
The Average True Range (ATR) for OPKO Health Inc. is set at 0.44, with the Price to Sales ratio for OPK stock in the period of the last 12 months amounting to 3.38. The Price to Book ratio for the last quarter was 1.96, with the Price to Cash per share for the same quarter was set at 0.03.
OPK stock trade performance evaluation
OPKO Health Inc. [OPK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.15. With this latest performance, OPK shares gained by 19.14% in over the last four-week period, additionally plugging by 209.24% over the last 6 months – not to mention a rise of 159.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OPK stock in for the last two-week period is set at 50.10, with the RSI for the last a single of trading hit 42.67, and the three-weeks RSI is set at 53.69 for OPKO Health Inc. [OPK]. The present Moving Average for the last 50 days of trading for this stock 4.01, while it was recorded at 5.13 for the last single week of trading, and 2.28 for the last 200 days.
OPKO Health Inc. [OPK]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and OPKO Health Inc. [OPK] shares currently have an operating margin of -21.79 and a Gross Margin at +29.34. OPKO Health Inc.’s Net Margin is presently recorded at -34.92.
Return on Total Capital for OPK is now -9.99, given the latest momentum, and Return on Invested Capital for the company is -16.27. Return on Equity for this stock declined to -18.49, with Return on Assets sitting at -13.23. When it comes to the capital structure of this company, OPKO Health Inc. [OPK] has a Total Debt to Total Equity ratio set at 19.57. Additionally, OPK Total Debt to Total Capital is recorded at 16.37, with Total Debt to Total Assets ending up at 13.68. Long-Term Debt to Equity for the company is recorded at 18.06, with the Long-Term Debt to Total Capital now at 15.10.
Reflecting on the efficiency of the workforce at the company, OPKO Health Inc. [OPK] managed to generate an average of -$51,661 per employee. Receivables Turnover for the company is 5.64 with a Total Asset Turnover recorded at a value of 0.38.OPKO Health Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.30.
Earnings per share (EPS) analysis for OPKO Health Inc. [OPK] stock
With the latest financial reports released by the company, OPKO Health Inc. posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OPK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for OPKO Health Inc. go to 12.00%.
OPKO Health Inc. [OPK]: Insider Ownership positions
There are presently around $827 million, or 25.30% of OPK stock, in the hands of institutional investors. The top three institutional holders of OPK stocks are: VANGUARD GROUP INC with ownership of 37,371,822, which is approximately -0.46% of the company’s market cap and around 0.50% of the total institutional ownership; BLACKROCK INC., holding 35,448,971 shares of the stock with an approximate value of $172.1 million in OPK stocks shares; and STATE STREET CORP, currently with $89.53 million in OPK stock with ownership of nearly 3.029% of the company’s market capitalization.
Positions in OPKO Health Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 90 institutional holders increased their position in OPKO Health Inc. [NASDAQ:OPK] by around 21,195,231 shares. Additionally, 86 investors decreased positions by around 20,340,660 shares, while 50 investors held positions by with 128,899,088 shares. The mentioned changes placed institutional holdings at 170,434,979 shares, according to the latest SEC report filing. OPK stock had 34 new institutional investments in for a total of 4,673,393 shares, while 34 institutional investors sold positions of 8,413,431 shares during the same period.